Orlistat

Journal of Drug Evaluation

Volumn 2, Issue 7, 2004, Pages 179-218

  Lean, M E J ^a,b   Campbell, P ^a,b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMIODARONE; AMITRIPTYLINE; ATORVASTATIN; BETA CAROTENE; CAPTOPRIL; CERIVASTATIN; CYCLOSPORIN; DIGOXIN; FUROSEMIDE; GLIBENCLAMIDE; LOSARTAN; METFORMIN; NIFEDIPINE; PHENTERMINE; PRAVASTATIN; RETINOL; SIBUTRAMINE; TETRAHYDROLIPSTATIN; VITAMIN D; WARFARIN;

ABDOMINAL PAIN; ABNORMAL FECES COMPOSITION; CANCER; CAUSE OF DEATH; CENTRAL NERVOUS SYSTEM DISEASE; CHOLELITHIASIS; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DEFECATION DISORDER; DIVERTICULITIS; DRUG ABSORPTION; DRUG ALCOHOL INTERACTION; DRUG BLOOD LEVEL; DRUG CARCINOGENICITY; DRUG EFFICACY; DRUG EXCRETION; DRUG ISOLATION; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; GALLBLADDER DISEASE; GALLSTONE; GASTROINTESTINAL SYMPTOM; GENOTOXICITY; HEALTH ECONOMICS; HEART DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPOGLYCEMIA; KIDNEY CYST; METABOLIC SYNDROME X; NEPHROLITHIASIS; OBESITY; REVIEW; RISK FACTOR; STONE FORMATION; STROKE; TERATOGENICITY;

EID: 23844497481     PISSN: 14791137     EISSN: None     Source Type: Journal    
DOI: 10.1080/14791130500121412     Document Type: Review

References (147)

1. Foreyt J, Goodrick K. The ultimate triumph of obesity. Lancet 1995;346:34-35.
2. Nutrition and Physical Activity Task Force. Department of Health. London: HMSO, 1995.
3. Prescott-Clark P, Primatesta P. Health Survey for England 1995. Department of Health, London: HMSO, 1997.
4. World Health Organization (WHO)/Food and Agriculture Organization (FAO) of the United Nations. Diet, nutrition and the prevention of chronic diseases. Report of a Joint WHO/FAO Expert Consultation. World Health Organ Tech Rep Ser, 2003: 916.
5. National Institute for Clinical Excellence (NICE). Guidance on the use of orlistat for the treatment of obesity in adults. NICE, March 2001. Technology Appraisal Guidance No.22.
6. Department of Health UK. Health Survey for England 2002: Latest Trends. December 2003.
7. World Health Organization (WHO). Obesity: preventing and managing the global epidemic. Report of a WHO consultation on obesity, Geneva 3-5 June 1997. WHO 1998.
8. Flegal KM, Carroll MD, Kuczmarski RJ, Johnson CL. Overweight and obesity in the United States: prevalence and trends, 1960-1994. Int J Obes 1998;22:39-47.
9. Gugelmin SA, Santos RV. Human ecology and nutritional anthropometry of adult Xavante Indians in Mato Grosso, Brazil [Article in Portugese]. Cad Saude Publica 2001;17(2):313-22.
10. Rotimi CN, Cooper RS, Ataman SL, et al. Distribution of anthropometric variables and the prevalence of obesity in populations of west African origin: the International Collaborative Study on Hypertension in Blacks (ICSHIB). Obes Res 1995;3 (Suppl 2):95s-105s
11. Colditz GA, Willett WC, Rotnitzky A, Manson JE. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 1995;122:481-6.
12. Manson JE, Colditz GA, Meir J, et al. A prospective study of obesity and risk of coronary heart disease in women. N Engl J Med 1990;322:882-9.
13. Lean MEJ, Powrie JK, Anderson AS, Garthwaite PH. Obesity, weight loss and prognosis in type 2 diabetes. Diabetic Med 1990;7:228-33.
14. United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphony-lureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
15. Lindahl B, Weinehall L, Asplund K, Hallmans G. Screening for impaired glucose intolerance: results from a population-based study in 21,057 individuals. Diabetes Care 1999;22:1988-92.
16. Willett WC, Manson JE, Stampfer MJ, et al. Weight, weight change, coronary heart disease in women. Risk within the 'normal' weight range. JAMA 1995;273(6): 461-5.
17. Manson JE, Willett WC, Stampfer MJ, et al. Body weight and mortality among women. N Eng J Med 1995;333:677-85.
18. Carmichael AR, Bates T. Obesity and breast cancer: a review of the literature. Breast 2004;13:85-92.
19. Key TJ, Schatkin A, Willett WC, et al. Diet, nutrition and the prevention of cancer. Public Health Nutr 2004;7:187-200.
20. Srinath Reddy K, Katan MB. Diet, nutrition and the prevention of hypertension and cardiovascular diseases. Public Health Nutr 2004;7:167-86.
21. Saris WHM, Blair SN, van Baak MA, et al. How much physical activity is enough to prevent unhealthy weight gain? Outcomes of the IASO 1st Stock Conference and consensus statement. Obes Res 2003;4:101-14.
22. Tsofliou F, Pitsiladis YP, Malkova D, Wallace AM, et al. Moderate physical activity permits acute coupling between serum leptin and appetite-satiety measures in obese women. Int J Obes 2003;27:1332-1339.
23. Hu FB, Li TY, Colditz GA, et al. Television watching and other sedentary behaviors in relation to risk of obesity and type 2 diabetes mellitus in women. JAMA 2003;289:1785-91.
24. Westrate JA, van het Hof KH, van den Berg H, et al. A comparison of the effect of free access to reduced fat products or their full fat equivalents on food intake, body weight, blood lipids and fat-soluble antioxidants levels and haemostasis variables. Eur J Clin Nutr 1998;52:389-95.
25. Astrup A, Ryan L, Grunwald GK, et al. The role of dietary fat in body fatness: evidence from a preliminary metaanalysis of ad libitum low-fat dietary intervention studies. Br J Nutr 2000;83(Suppl 1):S25-S32.
26. De Graaf C, Drijvers JJ, Zimmermanns NJ, van et Hof K, et al. Energy and fat compensation during long-term consumption of reduced fat products. Appetite 1997;29:301-323.
27. Bray GA. Nutrition and obesity: prevention and treatment. Nutr Metab Cardiovasc Dis 1999-9(Suppl to no.4): 21-32.
28. Blundell JE, Stubbs RJ. High and low carbohydrate and fat intakes: limits imposed by appetite and palatability and their implications for energy balance. Eur J Clin Nutr 1999;53 (Suppl 1):S148-S165.
29. Lean MEJ, James WPT. Metabolic effects of isoenergetic nutrient exchange over 24 hours in relation to obesity in women. Int J Obes 1988;12:15-28.
30. Labayen I, Forga L, Martinez. Nutrient oxidation and metabolic rate as affected by meals containing different proportions of carbohydrate and fat, in healthy young women. Eur J Nutr 1999;38:158-66.
31. Garrow JS. Obesity and related diseases. London: Churchill Livingstone, 1988.
32. Lean MEJ, James WPT. Prescription of diabetic diets in the 1980s. Lancet 1986;1:723-5.
33. Heitmann BL, Garby L. Patterns of long-term weight changes in overweight developing Danish men and women aged between 30 and 60 years. Int J Obes 1999;23:1074-8.
34. SIGN. Obesity in Scotland: integrating prevention with weight management. A National Clinical Guideline recommended for use in Scotland by the Scottish Intercollegiate Guidelines Network. Pilot edition, November 1996.
35. Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes 1992;16:397-415.
36. Williamson DF, Thompson TJ, Thun M, et al. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care 2000;23:1499-504.
37. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, et al., Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. New Engl J Med 2002;346(6):393-403.
38. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, et al. Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. New Engl J Med 2001;344(18):1343-1350.
39. Hollmann M, Runnebaum B, Gerhard I. Effects of weight loss on the hormonal profile in obese, infertile women. Hum Reprod 1996;11:1884-91.
40. Cummings JM, Rodning CB. Urinary stress incontinence among obese women: review of pathophysiology therapy. Int Urogynecol J Pelvic Floor Dysfunc 2000;11:41-4.
41. Lean ME. Is long-term weight loss possible? Br J Nutr 2000;83(Suppl 1):S103-S111.
42. Rissanen A, Lean M, Rössner S, et al. Predictive value of early weight loss in obesity management with orlistat: an evidence-based assessment of prescribing guidelines. Int J Obes 2003;27:103-109.
43. Weibel EK, Hadvary P, Hochuli E, et al. Lipstatin, an inhibitor of pancreatic lipase, produced by Streptomyces toxytricini. I. Producing organism, fermentation, isolation and biological activity. J Antibiot Tokyo 1987;40:1081-5.
44. Guerciolini R. Mode of action of orlistat. Int J Obes 1997;21(Suppl 3):S12-23.
45. Hauptman JB, Jeunet FS, Hartmann D. Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18-0647 (tetrahydrolipstatin). Am J Clin Nutr 1992;55: 309S-313S.
46. Shepard TY, Jensen DR, Blotner S, et al. Orlistat fails to alter postprandial plasma lipid excursions or plasma lipases in normal-weight male volunteers. Int J Obes Relat Metab Disord 2000;24:187-94.
47. Zhi J, Melia AT, Eggers H, et al. Review of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers. J Clin Pharmacol 1995a;35: 1103-8.
48. Zhi J, Mulligan TE, Hauptman JB. Long-term systemic exposure of orlistat, a lipase inhibitor, and its metabolites in obese patients. J Clin Pharmacol 1999;39:41-6.
49. Van Gaal LF, Broom JI, Enzi G, et al. Efficacy and tolerability of orlistat in the treatment of obesity: a 6-month dose-ranging study. Orlistat Dose-Ranging Study Group. Eur J Clin Pharmacol 1998;54:125-32.
50. Hvizdos KM, Markham A. Orlistat: a review of its use in the management of obesity. Drugs 1999;58:743-760.
51. Zhi J, Melia AT, Funk C, et al. Metabolic profiles of minimally absorbed orlistat in obese/overweight volunteers. J Clin Pharmacol 1996a;36:1006-11.
52. Zhi J, Melia AT, Guerciolini R, et al. Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther 1994;56:82-5.
53. Zhi J, Moore R, Kanitra L. The effect of short-term (21-day) orlistat treatment on the physiologic balance of six selected macrominerals and microminerals in obese adolescents. J Am Coll Nutr 2003a;22:357-362.
54. Pace DG, Blotner S, Guerciolini R. Short-term orlistat treatment does not affect mineral balance and bone turnover in obese men. J Nutr 2001;131:1694-9.
55. Drent ML, Larsson I, William-Olsson T, et al. Orlistat (RO 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study. Int J Obes Relat Metab Disord 1995;19:221-6.
56. Roche UK. Xenical® Summary of Product Characteristics. 08 October 2003.
57. Degen L, Matzinger D, Maecke H, et al. Influence of orlistat on gastric emptying rates of fats and solids in healthy subjects [abstract]. Gastroenterology 1998;114 (Pt 2 Suppl):740.
58. Goedecke JH, Barsdorf M, Beglinger C, et al. Effects of a lipase inhibitor (orlistat) on cholecystokinin and appetite in response to a high-fat meal. Int J Obes Relat Metab Disord 2003;27:1479-85.
59. Hartmann D, Güzelhan C, Zuiderwijk PBM. Lack of interaction between orlistat and oral contraceptives. Eur J Clin Pharmacol 1996;50:421-4.
60. Melia AT, Zhi J, Koss-Twardy SG, et al. The influence of reduced dietary fat absorption induced by orlistat on the pharmacokinetics of digoxin in healthy volunteers. J Clin Pharmacol 1995;35:840-3.
61. Melia AT, Mulligan TE, Zhi J. Lack of effect of orlistat on the bioavailability of a single dose of nifedipine extended-release tablets (Procardia XL®) in healthy volunteers. J Clin Pharmacol 1996a;36:352-5.
62. Melia AT, Mulligan TE, Zhi J. The effect of orlistat on the pharmacokinetics of phenytoin in healthy volunteers. J Clin Pharmacol 1996b;36:654-8.
63. Mück W, Adelmann H-G, Ruf T, et al. Lack of pharmacokinetic drug-drug interaction between orlistat and cerivastatin. Clin Drug Invest 2000;19:71-3.
64. Weber C, Tam YK, Schmidtke-Schrezenmeier G. Effect of the lipase inhibitor orlistat on the pharmacokinetics of four different antihypertensive drugs in healthy volunteers. Eur J Clin Pharmacol 1996;51:87-90.
65. Zhi J, Melia AT, Koss-Twardy SG, et al. The influence of orlistat on the pharmacokinetics and pharmacodynamics of glyburide in healthy volunteers. J Clin Pharmacol 1995b;35:521-5.
66. Zhi J, Moore R, Kanitra L, Mulligan TE. Pharmacokinetic evaluation of the possible interaction between selected concomitant medications and orlistat at steady state in healthy subjects. J Clin Pharmacol 2002;42:1011-9.
67. Oo CY, Akbari B, Lee S. Effect of orlistat, a novel anti-obesity agent, on the pharmacokinetics and pharmacodynamics of pravastatin in patients with mild hypercholesterolaemia. Clin Drug Invest 1999;17:217-23.
68. Melia AT, Zhi J, Zelasko R, et al. The interaction of the lipase inhibitor orlistat with ethanol in healthy volunteers. Eur J Clin Pharmacol 1998;54:773-7.
69. Le Beller C, Bezie Y, Chabatte C, et al. Co-administration of orlistat and cyclosporine in a heart transplant recipient. Transplantation 2000;70:1541-2.
70. Nägele H, Petersen B, Bonacker U, Rodiger W. Effect of orlistat on blood cyclosporine concentration in an obese heart transplant recipient. Eur J Clin Pharmacol 1999;55:667-9.
71. Schnetzler B, Kondo-Oestrreicher M, Vala D, et al. Orlistat decreases the plasma level of cyclosporine and may be responsible for the development of acute rejection episodes [letter]. Transplantation 2000;70:1540-1.
72. Zhi J, Moore R, Kanitra L, Mulligan TE. Effects of orlistat, a lipase inhibitor, on the pharmacokinetics of three highly lipophilic drugs (amiodarone, fluoxetine and simvastatin) in healthy volunteers. J Clin Pharmacol 2003b;43:428-35.
73. Zhi J, Melia AT, Koss-Twardy SG, et al. The effect of orlistat, an inhibitor of dietary fat absorption, on the pharmacokinetics of β > -carotene in healthy volunteers. J Clin Pharmacol 1996b;36:152-9.
74. Melia AT, Koss-Twardy SG, Zhi J. The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers. J Clin Pharmacol 1996c;36:647-53.
75. James WPT, Avenell A, Broom J, Whitehead J. A one-year trial to assess the value of orlistat in the management of obesity. Int J Obes 1997;21(Suppl 3):S24-S30.
76. Zavoral JH. Treatment with orlistat reduces cardiovascular risk in obese patients. J Hypertension 1998;16:2013-7.
77. Finer N, James WPT, Kopelman PG, et al. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes 2000;24:306-13.
78. Hill JO, Hauptman J, Anderson JW, et al. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study. Am J Clin Nutr 1999;69:1108-16.
79. Sjöström L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998;352:167-72.
80. Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat. JAMA 1999;281:235-42.
81. Rössner S, Sjöström L, Noack R, et al. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. Obes Res 2000; 8:49-61.
82. Hauptman J, Lucas C, Boldrin M, et al. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med 2000;9:160-7.
83. Krempf M, Louvet J-P, Allanic H, et al. Weight reduction and long-term maintenance after 18 months treatment with orlistat for obesity. Int J Obes 2003;27:591-597.
84. Torgerson JS, Hauptman J, Boldrin MN, Sjöström L. Xenical™ in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diab Care 2004;27:155-61.
85. NIH/NHLBI. Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). NIH publication no. 02-5215, Sept 2002.
86. Lindgärde F, on behalf of the orlistat Swedish Multimorbidity Study Group. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: The Swedish Multimorbidity Study. J Intern Med 2000;248:245-254.
87. Pataky Z, Golay A. Effect of treatment with orlistat for one-year on blood pressure in obese patients [abstract 582]. Int J Obes 1999;23 (Suppl 5):S175.
88. Heymsfield SB, Segal KR, Hauptman J, et al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med 2000;160:1321-6.
89. Chan JM, Rimm EB, Colditz GA, et al. Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care 1994;17:961-9.
90. Hauner H. The impact of pharmacotherapy on weight management in type 2 diabetes. Int J Obes Relat Metab Disord 1999;23 (Suppl 7):S12-7.
91. Wing RR, Koeske R, Epstein LH, et al. Long-term effects of modest weight loss in type II diabetic patients. Arch Intern Med 1987;147:1749-53.
92. Hanefeld M, Fischer S, Schmechel H, et al. Diabetes Intervention Study: multi-intervention trial in newly diagnosed NIDDM. Diabetes Care 1991;14:308-17.
93. United Kingdom Prospective Diabetes Study (UKPDS) Group. Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years (UKPDS 13). BMJ 1995;310:83-8.
94. Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. Diabetes Care 1998;21:1288-94.
95. Hanefeld M, Sachse G. The effects of orlistat on body weight and glycaemic control in over weight patients with type 2 diabetes: a randomised, placebo-controlled trial. Diabetes Obes Metab 2002;4:415-23.
96. Kelley DE, Bray GA, Pi-Sunyer FX, et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes. Diabetes Care 2002;25:1033-41.
97. Miles JM, Leiter L, Hollander P, et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care 2002;25:1123-8.
98. Tong PC, Lee ZS, Sea MM, et al. The effect of orlistat-induced weight loss, without concomitant hypocaloric diet on cardiovascular risk factors and insulin sensitivity in young obese Chinese subjects with or without type 2 diabetes. Arch Intern Med 2002;162:2428-35.
99. Halpern A, Mancini MC, Suplicy H, et al. Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients. Diabetes Obes Metab 2003;5:180-8.
100. Kelley DE, Kuller LH, McKolanis TM, et al. Effects of moderate weight loss and orlistat on insulin resistance, regional adiposity, and fatty acids in type 2 diabetes. Diabetes Care 2004;27:33-40.
101. Wirth A, Platon J. Effect of orlistat on body weight and co-morbidities in clinical practice: the xx1-primary health care observational trial. Int J Obes 2001;25(Suppl 2):S23-S24.
102. Muls E, Kolanowski J, Scheen A, Van Gaal L. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolaemia: a randomized, double-blind, placebo-controlled, multicentre study. Int J Obes 2001;25:1713-21.
103. Broom I, Hughes E, Dodson P, Reckless J. The role of orlistat in the treatment of obese patients with mild to moderate hypercholesterolaemia: consequences for coronary risk. Br J Cardiol 2002;9:460-8.
104. Petrogiannopoulos C, Kalogeropoulos S, Latsios GS, et al. Orlistat use in overweight women with mild hypercholesterolaemia. Int J Clin Pharm Res 2002;XXII:85-8.
105. Lucas CP, Boldrin MN, Reaven GM. Effect of orlistat added to diet (30% of calories from fat) on plasma lipids, glucose, and insulin in obese patients with hypercholesterolaemia. Am J Cardiol 2003;91:961-4.
106. Scaglione R, Parrinello G, Corrao S, et al. Prevalence of obesity and ischaemic heart disease in hypertensive subjects. Eur Rev Med Pharmacol Sci 1997;1:69-75.
107. Sharma AM. Obesity and cardiovascular risk. Growth Horm IGF Res 2003;13(Suppl A):S10-7.
108. Stevens VJ, Corrigan SA, Obarzanek E, et al. Weight loss intervention in phase 1 of the Trials of Hypertension Prevention. The TOHP Collaborative Research Group. Arch Intern Med 1993;153:849-58.
109. He J, Whelton PK, Appel LJ, et al. Long-term effects of weight loss and dietary sodium reduction on incidence of hypertension. Hypertension 2000;35:544-9.
110. Davis BR, Blaufox MD, Oberman A, et al. Reduction in long-term antihypertensive medication requirements. Effects of weight reduction by dietary intervention in overweight persons with mild hypertension. Arch Intern Med 1931;153:1773-82.
111. McCarron DA, Reusser ME. Body weight and blood pressure regulation. Am J Clin Nutr 1996;63:423S-425S.
112. Bakris G, Calhoun D, Egan B, et al. Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. J Hypertens 2002;20:2257-67.
113. Sharma AM, Golay A. Effect of orlistat-induced weight loss on blood pressure and heart rate in obese patients with hypertension. J Hypertens 2002;20:1873-8.
114. Harrison SA, Fincke C, Helinski D, Torgerson S. Orlistat treatment in obese, non-alcoholic steatohepatitis patients: a pilot study [abstract 406A]. Hepatology 2002a;36:971.
115. Kumar KS, Malet PF. Nonalcoholic steatohepatitis. Mayo Clin Proc 2000;75:733-9.
116. Harrison SA, Kadakia S, Lang KA, Schenker S. Nonalcoholic steatohepatitis: what we know in the new millennium. Am J Gastroenterol 2002b;97:2714-24.
117. Assy N, Svalb S, Hussein O. Orlistat (Xenical) reverses fatty liver disease and improves hepatic fibrosis in obese patients with NASH [abstract]. Hepatology 2001;34(Suppl):458A.
118. Harrison SA, Ramrakhiani S, Brunt EM, et al. Orlistat in the treatment of NASH: a case series. Am J Gastroenterol 2003;98:926-30.
119. Koliouskas D, Savopoulos C, Koliouskas D, et al. The efficacy and safety of atorvastatin, omega 3 fatty acid and orlistat on non-alcoholic liver disease (NASH) [abstract 535]. J Hepatol 2002;36(Suppl 1):148.
120. Reaven G, Segal K, Hauptman J, et al. Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X. Am J Cardiol 2001;87:827-31.
121. NCEP. Executive Summary of the third report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation and Treatment of high blood cholesterol in adults (Adult treatment panel III). JAMA 2001;285:2486-97.
122. Fontaine KR, Cheskin U, Barofsky I. Health-related quality of life in obese patients seeking treatment. J Fam Pract 1996;43:265-70.
123. Sullivan M, Karlsson J, Sjöström L, et al. Swedish obese subjects (SOS) - an intervention study of obesity. Baseline evaluation of health and psychosocial functioning in the first 1743 subjects examined. Int J Obes 1993;17:503-12.
124. Fontaine KR, Barofsky I. Obesity and health-related quality of life. Obes Rev 2001;2:173-82.
125. Lean MEJ, Lara J. Quality of life in the management of obesity. Progress in Obesity Research: 9. Neto, Halpern & Bouchard (Eds). France: John Libbey, 2003:859-865.
126. Lean MEJ. Obesity - what are the treatment options? Exp Clin Endocrinol Diabetes 1998;106 (Suppl 2):22-6.
127. Stolshek B, Mathias S, Pasta D, et al. Health-related quality of life (HRQoL) during treatment with orlistat (Xenical™) [abstract 518]. Int J Obes 1999;23(Suppl 5):S158.
128. Mathias S, Pasta D, Prebil, et al. Quality of life during treatment with orlistat (Xenical™) [abstract]. Obes Res 1997;5(Suppl 1):69S.
129. Brown JB, Pedula KL, Bakst AW. The progressive cost of complications in type 2 diabetes mellitus. Arch Intern Med 1999;159:1873-80.
130. Foxcroft DR, Milne R. Orlistat for the treatment of obesity: rapid review and cost effectiveness model. Obes Rev 2000;1:121-6.
131. Foxcroft D, Ludders J. Orlistat for the Treatment of Obesity. Southampton: Wessex Institute for Health Research and Development, 1999. Report No. 101. 49.
132. Roche. Cost-utility analysis of orlistat. Company submission, 2000.
133. Lamotte M, Annemans L, Lefever A, et al. A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients. Diabetes Care 2002;25:303-8.
134. Maetzel A, Ruof J, Covington M, Wolf A. Economic evaluation of orlistat in overweight and obese patients with type 2 diabetes mellitus. Pharmacoeconomics 2003;21:501-12.
135. Lee KK, You JH, Ho SS, et al. A pharmacoeconomic analysis of weight-reduction therapy in a hypothetical cohort of obese Chinese patients with impaired glucose tolerance [abstract]. Value in Health 2001;4:116.
136. Froehlich F, Hartmann D, Guezelhan C, et al. Influence of orlistat on the regulation of gallbladder contraction in man: a randomized double-blind placebo-controlled crossover study. Dig Dis Sci 1996;41:2404-8.
137. Herrara MF, Lozano-Salazar RR, Gonzalez-Barranco J, Rull JA. Diseases and problems secondary to massive obesity. Eur J Gastroenterol Hepatol 1999;11:63-7.
138. Zoss I, Piec G, Horber FF. Impact of orlistat therapy on weight reduction in morbidly obese patients after implantation of the Swedish adjustable gastric band. Obes Surg 2002;12:113-7.
139. Miller K, Miller E. Orlistat® treatment after failure and complications of the adjustable gastric banding system in morbid obesity - results of a matched controlled prospective pilot study [abstract 078]. Int J Obes 2001;25:S27-S28.
140. Muratori F, Vignati F, Di Sacco G. Efficacy of orlistat on weight-loss in different degrees of obesity (preliminary data) [abstract P302]. Int J Obes 2001;25(Suppl 2):S113.
141. Wadden TA, Berkowiz RI, Womble LG, et al. Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial. Obes Res 2000;8:431-7.
142. Jolliffe D. Extent of overweight among US children and adolescents from 1971-2000. Int J Obes 2004;28:4-9.
143. Norgren S, Danielsson P, Jurold R, et al. Orlistat treatment in prepubertal children: a pilot study. Acta Paediatr 2003;92:666-670.
144. McDuffie JR, Calis KA, Uwaifo GI, et al. Three-month tolerability of orlistat in adolescents with obesity-related comorbid conditions. Obes Res 2002a;10:642-50.
145. McDuffie JR, Calis KA, Booth SL, et al. Effects of orlistat on fat-soluble vitamins in obese adolescents. Pharmacother 2002b;22:814-22.
146. Williamson DF, Pamuk E, Thun M, et al. Prospective study of intentional weight loss and mortality in never-smoking overweight US white women aged 40-64 years. Am J Epidemiol 1995;141:1128-41.
147. Williamson DF. Weight loss and mortality in persons with type-2 diabetes mellitus: a review of the epidemiological evidence. Exp Clin Endocrinol Diabetes 1998;106(Suppl 2):14-21.